UK Companies House feature
AMAROX LIMITED
Cash
£93K
-32.5% vs 2024
Net assets
£12M
-1.8% vs 2024
Employees
—
Average over period
Profit before tax
—
Period ending 2025-03-31
Profile
- Company number
- 10997632
- Status
- Active
- Incorporation
- 2017-10-05
- Last accounts made up
- 2025-03-31
- Account category
- GROUP
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Net assets
6-year trend · vs UK Healthcare median
Accounts
6-year trend · latest 2025-03-31
| Metric | Trend | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | — | — | |
| Profit before tax | — | — | — | — | — | — | |
| Net profit | — | — | — | — | -£1,851,043 | -£829,476 | |
| Cash | £690,573 | — | — | — | £137,797 | £93,018 | |
| Total assets less current liabilities | -£2,333,700 | — | — | — | £29,512,441 | £28,859,617 | |
| Net assets | -£2,555,587 | — | — | — | £11,854,613 | £11,640,720 | |
| Equity | -£2,555,587 | -£255,120 | — | £2,932,616 | £11,854,613 | £11,640,720 | |
| Average employees | 4 | — | — | — | — | — | |
| Wages | — | — | — | — | — | — |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated (group)
- Auditor
- Smartax Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“We draw attention to Note 2 in the financial statements which indicates that the group incurred a net loss of £3,388,859 during the year ended 31 March 2025 and, as at that date, had net current liabilities of £672,003. As stated in Note 2, the group is reliant on the financial support of its immediate parent company. There is, however, no contractual certainty that this financial support will continue, as the support confirmations providided are not legally binding. These events and conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the group's and company's ability to continue as a going concern.”
Subsidiaries
- Tarbis Farma S.L · 99.99% held · Spain · selling and distribution of pharmaceutical products
- Amarox Pharma B.V · 100% held · Netherlands · selling and distribution of pharmaceutical products
- Amarox Pharma France · 100% held · France · selling and distribution of pharmaceutical products
Significant events
- “Following the year end, in May 2025, the group incorporated a new subsidiary, Amarox Pharma Sp. z o.o, in Poland.”
- “In June 2025 the group disposed of its 100% shareholding in Amarox Pharma B.V to its immediate parent company. As the transaction occurred after the reporting date, it has not been reflected in these financial statements. The transaction resulted in a gain of approximately £126,000, which will be recognised in the next financial year.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ATTUNURI, Venkata Narasa Reddy | Director | 2017-10-05 | Dec 1963 | Indian |
| BHEEMIREDDY, Murali Krishna Reddy | Director | 2020-09-01 | Jun 1977 | Indian |
| PRAKASH, Manoj | Director | 2018-03-01 | Feb 1963 | British |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| KAMBHAM, Raveendranatha Reddy | Director | 2017-10-05 | 2023-07-21 |
| PANDA, Chandramani | Director | 2017-10-05 | 2020-08-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Hetero Fzco | Corporate entity | Shares 75–100%, Appoints directors | 2025-07-22 | Active |
Filing timeline
Last 20 of 33 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-14 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2026-03-26 | CH01 | officers | change person director company with change date |
| 2026-03-26 | CH01 | officers | change person director company with change date |
| 2025-12-23 | AA | accounts | accounts with accounts type group |
| 2025-07-30 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2025-07-30 | PSC09 | persons-with-significant-control | withdrawal of a person with significant control statement |
| 2025-02-11 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-12-19 | AA | accounts | accounts with accounts type group |
| 2024-05-30 | AA | accounts | accounts with accounts type group |
| 2024-02-29 | CS01 | confirmation-statement | confirmation statement with updates |
| 2024-02-29 | SH01 | capital | capital allotment shares |
| 2024-01-24 | RESOLUTIONS | resolution | resolution |
| 2023-08-16 | CS01 | confirmation-statement | confirmation statement with updates |
| 2023-07-24 | TM01 | officers | termination director company with name termination date |
| 2022-11-09 | AA | accounts | accounts with accounts type small |
| 2022-11-07 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-10-26 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-08-24 | AA | accounts | accounts with accounts type small |
| 2020-11-20 | AA | accounts | accounts with accounts type small |
| 2020-11-18 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory